Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients
The current standard of care for patients with chronic hepatitis C virus (HCV) infection is a combination of direct-acting antiviral agents (DAAs). However, rare clinical trials have been reported on the combination regimen of sofosbuvir (SOF) with ombitasvir, paritaprevir, and ritonavir (OBV/PTV/r) plus ribavirin (RBV) for treated patients with HCV genotype 4 (GT4) infection.
To clarify the retreatment efficacy and safety of the recent regimen, SOF with OBV/PTV/r + RBV, for chronic HCV GT4-experienced patients who failed treatment with DAA-based regimens.
A total of 113 treatment-experienced patients were allocated for the completion of their treatment period. The enrolled patients were treated orally with SOF plus a fixed dose combination of OBV/PTV/r + RBV, which was administered orally based on the patients’ tolerability. The primary end point was a sustained virological response (HCV RNA < 15 IU/mL), observed 12 weeks after the end of the treatment (SVR12).
Among all patients, the treatment-experienced patients with SOF plus OBV/PTV/r + RBV had a higher SVR12 rate (97%; 109/113). Further, SVR12 was achieved by 98% (81/83) of non-cirrhotic patients and 93% (28/30) of cirrhotic patients. Additionally, the most common adverse events reported included fatigue, headache, insomnia, nausea, and dyspnea.
The recent multi-targeted regimen of SOF plus OBV/PTV/r + RBV was well tolerated and achieved excellent SVR rates among retreatment-experienced Egyptian patients with prior DAA treatments failure, thus providing an alternative regimen for the retreatment of difficult-to-cure HCV GT4 patients.
KeywordsEgyptian patients Sofosbuvir Ombitasvir Paritaprevir Ritonavir Ribavirin
The authors acknowledge with grateful appreciation to the staff member of the National Treatment Centers in Beni-Suef, Egypt. We thank the patients and their families, as well as Mss/Asmaa Mahmoud Gaber for her generous help in figures preparation.
Compliance with ethical standards
Conflict of interest
The authors declare that there is no conflict of interest.
- 12.Infectious Diseases Society of America (IDSA). Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org; 2016. Accessed 24 June 2016.
- 21.U.S. Food and Drug Administration. FDA approves Vosevi for Hepatitis C. July 18, 2017. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm567467.htm.
- 22.European Medicines Agency. Summary of opinion: Vosevi” (PDF). http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004350/WC500229884.pdf; 22 June 2017.
- 24.Zeuzem S, Flamm S, Tong M, et al. A randomized, controlled, phase 3 trial of sofosbuvir velpatasvir-voxilaprevir or sofosbuvir-velpatasvir for 12 weeks in direct-acting antiviral-experienced patients with genotype 1–6 HCV infection: the POLARIS-4 study. American Association for the Study of Liver Disease (AASLD), November 2016. Boston, USA. http://www.natap.org/2016/AASLD/AASLD_18.htm.